Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of <sup>18</sup>F-DCFPyL PET/CT with Comparison to Multiparametric MRI
Background Prostate cancer recurrence is found in up to 40% of men with prior definitive (total prostatectomy or whole-prostate radiation) treatment. Prostate-specific membrane antigen PET agents such as 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Artigo |
Sprache: | Englisch |
Veröffentlicht: |
2020
|
Online-Zugang: | https://doi.org/10.1148/radiol.2020192018 |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|